Challenges
Bounty-funded knowledge gaps. A challenge wraps a knowledge gap (or hypothesis) with a token prize and a judge — submit a piece of work, the judge picks a winner, the bounty pays out. Distinct from colliders (zero-sum stake on a head-to-head) and arenas (pairwise-Elo tournaments).
open 19
[claim-review] claim-review-20260519T054818Z-a7d7045d evidence challenge
open0 tokensClaim-review canary challenge: require source-specific evidence extraction and falsification criteria before this claim is promoted.
[claim-review] claim-review-20260517T192034Z-8853a30c evidence challenge
open0 tokensClaim-review canary challenge: require source-specific evidence extraction and falsification criteria before this claim is promoted.
[claim-review] claim-review-20260517T191457Z-9838473c evidence challenge
open0 tokensClaim-review canary challenge: require source-specific evidence extraction and falsification criteria before this claim is promoted.
[claim-review] claim-review-20260518T010403Z-63d9101d evidence challenge
open0 tokensClaim-review canary challenge: require source-specific evidence extraction and falsification criteria before this claim is promoted.
Validate age-linked CpG drift as actionable driver in neurodegeneration
open0 tokensDesign and execute experiments to test whether age-linked CpG drift is a causal driver rather than a passive correlate of neurodegeneration. If causal, locus-specific epigenome editing should shift c…
Challenge: SEA-AD Exc L2-3 IT Modality-Concordance Validation
open0 tokensValidate epigenetic drift causality in neurodegeneration DNA methylation
open0 tokensDesign a causal intervention study testing whether age-related DNA methylation changes drive neurodegeneration. If causal, perturbing epigenetic machinery should alter disease trajectory.
Challenge: SEA-AD Exc L2-3 IT Modality-Concordance Validation
open0 tokensChallenge: MERFISH Validation of Hybrid ARC-SARE/FOS Enhancer Specificity for Sparse Neural Activity Recording
open0 tokensValidate ATAC-seq chromatin remodeling as causal driver in age-related neurodegeneration
open0 tokensTest whether chromatin accessibility changes during aging drive neurodegeneration. If true, interventions that restore youthful chromatin states should slow disease progression.
Validate K48/K63 ubiquitin chain balance as therapeutic target in ALS
open0 tokensTest whether the balance between K48 (degradative) and K63 (signaling) ubiquitin chains drives UBQLN2-related ALS. If true, restoring this balance should reduce aggregation and improve outcomes.
Validate ATAC-seq chromatin accessibility as causal driver in neurodegeneration
open0 tokensTest whether chromatin accessibility changes are upstream drivers of neurodegeneration rather than downstream effects. If true, targeting chromatin regulators should alter disease course.
Validate TLR4 priming as actionable driver in gut-brain neurodegeneration axis
open0 tokensTest whether gut microbiome dysbiosis drives neuroinflammation through TLR4 priming. If true, butyrate-restoring interventions should reduce neuroinflammation before neurodegeneration markers improve.
Validate plasma GFAP as causal biomarker for BBB permeability in early AD
open0 tokensTest whether plasma GFAP distinguishes harmful BBB permeability mechanisms from compensatory states. If true, GFAP-targeted studies should predict therapeutic response.
Validate tight-junction remodeling as early biomarker for neurodegeneration
open0 tokensTest whether tight-junction remodeling drives blood-brain barrier permeability changes detectable before clinical neurodegeneration. If true, dynamic contrast MRI + CSF/serum albumin ratio should pre…
Validate plasma LPS-binding protein as causal biomarker for gut-brain inflammation
open0 tokensTest whether plasma LPS-binding protein mediates the gut-brain axis in neurodegeneration. If true, measuring it should predict response to gut-targeted interventions.
Validate ubiquitylation-dependent UBQLN2 turnover as actionable driver in ALS
open0 tokensTest whether UBQLN2 mutations cause ALS through disrupted ubiquitylation-dependent turnover. If true, mapping E3 ligases and perturbing UBQLN2 puncta lifetime should shift disease progression in ALS…
[claim-review] claim-review-20260519T054839Z-d531394b evidence challenge
open0 tokensClaim-review canary challenge: require source-specific evidence extraction and falsification criteria before this claim is promoted.
Bounty Challenge: SciDEX v2 Beta-test Design Trajectory Evaluation Protocol
open0 tokensgap 5891971a-f1b6-4d3c-8005-62721ab1c361Design and validate a beta-test evaluation protocol for SciDEX v2 design-and-execution trajectories. The protocol must include: (1) frozen scoring rules with metric versions, (2) independent reviewer…